|
| | Publication Year | Title | Author(s) |
| 1 | 22-Sep-2023 | Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour. | Klein, Oliver ; Palmer, Jodie ; Behren, Andreas; Cebon, Jonathan S ; Kee, Damien |
| 2 | 1-Apr-2023 | Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers? | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 3 | Nov-2021 | Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. | Klein, Oliver ; Kee, Damien ; Gao, Bo; Markman, Ben; da Gama Duarte, Jessica; Quigley, Luke; Jackett, Louise A ; Linklater, Richelle; Strickland, Andrew; Scott, Clare; Mileshkin, Linda; Palmer, Jodie ; Carlino, Matteo; Behren, Andreas; Cebon, Jonathan S |
| 4 | 29-Apr-2021 | Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Carlino, Matteo S; Underhill, Craig; Palmer, Jodie ; Power, Daniel; Cebon, Jonathan S ; Behren, Andreas |
| 5 | 12-Apr-2021 | Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. | Klein, Oliver ; Senko, Clare ; Carlino, Matteo S; Markman, Ben; Jackett, Louise A ; Gao, Bo; Lum, Caroline; Kee, Damien ; Behren, Andreas; Palmer, Jodie ; Cebon, Jonathan S |
| 6 | 1-Sep-2020 | Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 7 | Sep-2020 | Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Michael, Michael; Underhill, Craig; Carlino, Matteo S; Jackett, Louise A ; Lum, Caroline; Scott, Clare; Nagrial, Adnan; Behren, Andreas; So, Jane Y; Palmer, Jodie ; Cebon, Jonathan S |
| 8 | 5-Sep-2019 | Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. | Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S |
| 9 | 12-Nov-2018 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. | Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen |
Loading...
2
0
20
0
false